<DOC>
	<DOCNO>NCT02457845</DOCNO>
	<brief_summary>This study clinical trial determine safety inject G207 ( new experimental virus therapy ) recurrent progressive brain tumor . The safety combine G207 single low dose radiation , design enhance virus replication tumor cell killing , also test . Funding Source - FDA OOPD</brief_summary>
	<brief_title>HSV G207 Alone With Single Radiation Dose Children With Progressive Recurrent Supratentorial Brain Tumors</brief_title>
	<detailed_description>Outcomes child recurrent progressive supratentorial malignant brain tumor poor , lack effective salvage therapy patient fails standard treatment . G207 oncolytic herpes simplex virus-1 ( HSV ) successfully engineer introduce mutation virus enable selectively replicate kill cancer cell , normal cell . Replication G207 tumor kill infected tumor cell , cause tumor cell act factory produce new virus . These virus particle release tumor cell dy , proceed infect tumor cell vicinity , continue process tumor kill . In addition direct oncolytic activity , virus engenders anti-tumor immune response ; virus immunogenic produce debris field expose cancer cell antigens immune cell target cancer cell . Thus , oncolytic effect virus immune response virus stimulate provide one-two punch attack cancer cell . In preclinical study , single 5 Gy dose radiation within 24 hour virus inoculation tumor increase virus replication tumor cell kill . The University Alabama Birmingham conduct three phase I trials G207 inject recurrent tumor alone combine single dose radiation adult recurrent high-grade glioma . In trial , high dos ( 3 x 10^9 plaque-forming unit ) virus safely inject directly tumor surround brain tissue without serious toxicity . Radiographic neuropathologic evidence antitumor response see patient . Preclinical laboratory study demonstrate variety aggressive pediatric brain tumor type sensitive G207 . This study phase I , open-label , single institution clinical trial G207 alone combine single low dose radiation child recurrent progressive supratentorial brain tumor . The primary goal determine safety . The secondary aim obtain preliminary information effectiveness immune response G207 . A traditional 3 + 3 design use four patient cohort . The first two cohort receive G207 one two dos , second two cohort receive G207 one two dos follow 5 Gy dose radiation .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Supratentorial Neoplasms</mesh_term>
	<criteria>Age ≥ 36 month &lt; 19 year Pathologically proven malignant supratentorial brain tumor ( include glioblastoma multiforme , giant cell glioblastoma , anaplastic astrocytoma , primitive neuroectodermal tumor , ependymoma , atypical teratoid/rhabdoid tumor , germ cell tumor , highgrade malignant tumor ) progressive recurrent despite standard care include surgery , radiotherapy , and/or chemotherapy Lesion must &gt; 1.0 cm diameter surgically accessible determined MRI Patients must fully recover acute treatment related toxicity prior chemotherapy , immunotherapy radiotherapy prior enter study . Myelosuppressive chemotherapy : patient must receive last dose least 3 week prior ( least 6 week nitrosurea ) Investigational/Biologic agent : patient must recover acute toxicity potentially related agent receive last dose ≥ 7 day prior enter study ( period must extend beyond time adverse event know occur agent know adverse event ≥ 7 day ) Monoclonal antibody : At least 3 halflives must elapse prior study entry Radiation : Patients must receive last fraction craniospinal radiation ( &gt; 24 Gy ) total body irradiation ≥ 3 month prior study entry . Patients must receive focal radiation symptomatic metastatic site local palliative radiation &gt; 4 week prior study entry . Autologous bone marrow transplant : Patients must ≥ 3 month since transplant prior study entry . Normal hematological , renal liver function ( Absolute neutrophil count &gt; 1000/mm3 , Platelets &gt; 100,000/mm3 , Prothrombin Time ( PT ) Partial Thromboplastin Time ( PTT ) &lt; 1.3 x control , Creatinine ≥ 70 mL/min/1.73 m2 , Total Bilirubin &lt; 1.5 mg/dl , Transaminases &lt; 3 time upper limit institutional norm ) Patients &lt; 10 year , Modified Lansky score ≥ 60 ; patient &gt; 10 year , Karnofsky score ≥ 60 Patient life expectancy must least 8 week Written inform consent accordance institutional FDA guideline must obtain patient legal guardian Acute infection , granulocytopenia medical condition preclude surgery Pregnant lactating female Prior history encephalitis , multiple sclerosis , central nervous system ( CNS ) infection Tumor involvement would require ventricular , cerebellar brainstem inoculation Prior participant experimental viral therapy ( e.g. , adenovirus , retrovirus herpes virus protocol ) Required steroid increase within 1 week prior injection Known HIV seropositivity Concurrent therapy drug active HSV ( acyclovir , valaciclovir , penciclovir , famciclovir , gancyclovir , foscarnet , cidofovir ) immunosuppressive drug therapy ( except dexamethasone prednisone ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Brain Tumor , Recurrent</keyword>
	<keyword>Glioma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>Oligodendroglioma</keyword>
	<keyword>Rhabdoid Tumor</keyword>
	<keyword>Cerebral Primitive Neuroectodermal Tumor</keyword>
	<keyword>PNET</keyword>
	<keyword>Ependymoma</keyword>
	<keyword>Germ Cell Tumor</keyword>
	<keyword>Choroid Plexus Carcinoma</keyword>
	<keyword>Oncolytic Virus Therapy</keyword>
	<keyword>Virotherapy , Oncolytic</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pediatrics</keyword>
</DOC>